|
|
||
 |
| U.S.-based biopharmaceutical company NeoImmuneTech's CEO Yang Se-hwan speaks during the firm's IPO press conference held at the Conrad Seoul on Yeouido in the capital, Monday. Founded in 2014, the T-cell-focused company is dedicated to the discovery of novel immune-therapeutics in cooperation with major global pharmaceutical companies. The firm's stock allotment subscription period is for two days in early May and it's expected to make its KOSDAQ debut in mid-March. Courtesy of NeoImmuneTech |
2 people die after getting COVID-19 vaccine 
Transgender ex-soldier forced to discharge found dead at home 
2 Korean nursing home residents die after getting AstraZeneca vaccine 
Management of foreigners' ID to be strengthened 
'Chinese virus, get out!': Chinese lecturer assaulted in UK amid fears of anti-Asian racism 
[INTERVIEW] 'We fight the gov't for our rights and future' 
Hate crimes against Asian American on rise in US amid pandemic 
Gov't to push for 'quarantine-free corridors' to support ailing aviation industry 
Coupang Eats' new delivery fee policy hits riders 
New virus cases bounce back to over 400 
